<DOC>
	<DOC>NCT02782858</DOC>
	<brief_summary>The humanised IgG4 monoclonal antibody GNbAC1 targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retrovirus (HERV-W MSRV), which may play a critical role in multiple sclerosis (MS). This study evaluates the effect on MRI lesions parameters, the safety and pharmacokinetics of GNbAC1 in patients with relapsing remitting multiple sclerosis.</brief_summary>
	<brief_title>Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>Main For male or female with reproductive potential, use of reliable means of contraception; RRMS according to the 2010 revised McDonald criteria; Disease activity characterised by at least one documented relapse within the last 12 months and /or at least one Gdenhancing T1 lesion at selection or evidenced within the last 3 months; EDSS score &lt; 6.0. Main Patients suffering from Secondary Progressive MS and Primary Progressive MS at screening; Pregnant and nursing women.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Multiple Sclerosis Relapsing-Remitting</keyword>
	<keyword>GNbAC1</keyword>
	<keyword>MRI</keyword>
	<keyword>Monoclonal antibody</keyword>
	<keyword>Multiple Sclerosis associated retrovirus MSRV</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>HERV-W</keyword>
</DOC>